Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.
She has a BA in English from Penn State University. You can connect with Maggie on LinkedIn.
More, Better Linkage to Care Needed to Optimize HIV-Related Support Outcomes
March 15th 2022This new meta-analysis from World Health Organization and University of Cape Town investigators analyzed adverse posthospitalization discharge outcomes and related risk factors among persons living with HIV.
Read More
Greater CVD Risk Seen Among Individuals With SMI
March 11th 2022This new study investigated cardiovascular disease (CVD) risk outcomes among patients with a serious mental illness (SMI) attending primary care clinics that were part of HealthPartners and Park Nicollet in Minnesota and Wisconsin.
Read More
HIV-1 Virulence Appears More Potent Among Heterosexual Individuals
March 10th 2022This new study evaluated the influence of transmission bottlenecks on HIV-1 infection virulence by comparing outcomes between penile-vaginal intercourse and anal intercourse, and found more severe disease among heterosexual individuals compared with men who have sex with men.
Read More
A DCIS Diagnosis Introduces Physical, Emotional Uncertainty for Many Women
March 10th 2022This new study focused on the patient perspective following a diagnosis of ductal carcinoma in situ (DCIS), a noninvasive type of breast cancer also referred to as stage 0 or pre-cancer, as well as their concerns over follow-up
Read More
Worsened Heart Failure Mortality Seen in Presence of Hyperlactatemia
March 8th 2022A new study of patients receiving care for acute heart failure at Rambam Health Care Campus in Haifa, Israel, investigated how their clinical outcomes might be affected by elevated lactate levels and primary acid-base disorders.
Read More
Inadequate Testing for CAD Infuses Heart Failure Space
March 4th 2022This new analysis of commercial and Medicare Advantage claims from all 50 states investigated utilization of and testing trends for coronary artery disease (CAD) among adults aged 18 and older presenting with new-onset heart failure.
Read More
AstraZeneca’s Camille Hertzka: Testing for HRR Mutation Status in mCRPC Helps Inform Risk Profile
March 2nd 2022Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses why it is important to test for HRR gene mutation status and appropriateness of olaparib use in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Read More
Dr Debra Patt Discusses Ongoing Pandemic-Related Delays in Cancer Screenings
March 2nd 2022Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses roadblocks to cancer screenings first thrown up by the COVID-19 pandemic in 2020 and that continue to reverberate today.
Read More
Measures of Resistant Hypertension Linked to Worse Outcomes Among Black Adults
March 1st 2022A new study has investigated the influence of xanthine oxidase activity and mitochondrial DNA damage–associated molecular patterns on heart failure and cardiac remodeling among Black adults with resistant hypertension.
Read More
Possibility of Breast Cancer Overdiagnosis Should Inform Mammography Decisions
February 28th 2022This new study of women who underwent mammographic screening for breast cancer at a Breast Cancer Surveillance Consortium facility between 2000 and 2018 investigated potential implications of overdiagnosis.
Read More
CROI Abstract Shows Drop in Neurocognitive Deficit Among PLWH
February 26th 2022An abstract presented at this year’s Conference on Retroviruses and Opportunistic Infections (CROI) bore out the results of an Italian investigation into a potential link between persons living with HIV (PLWH) taking newer antiretroviral therapies and neurocognitive disorder prevalence.
Read More
AstraZeneca's Camille Hertzka Discusses Interim PROpel Trial Findings in mCRPC
February 25th 2022Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses principal findings of the PROpel trial, which compared outcomes between olaparib plus abiraterone vs abiraterone alone in men with metastatic castration-resistant prostate cancer (mCRPC).
Read More
Further Analysis Needed to Incorporate Liquid Biopsy in the Community Setting
February 23rd 2022This new study, conducted among individuals receiving treatment at Cancer Center of Kansas, investigated the potential benefits of incorporating liquid biopsy into community-based oncology practices.
Read More
Further Study Needed to Better Understand HFpEF, Normal NT-proBNP Relationship
February 22nd 2022This new study investigated the relationship between cardiac function and hemodynamics among individuals presenting with heart failure with preserved ejection fraction (HFpEF) and normal levels of N-terminal prohormone B-type natriuretic peptide (NT-proBNP).
Read More
Interferon-α Therapy Bests Donor Lymphocyte Infusion in AML Comparison Study
February 18th 2022A new retrospective study of patients with high-risk t(8;21) acute myeloid leukemia (AML) investigated outcomes from 2 therapies following return of minimal residual disease–positive status after allogeneic hematopoietic stem cell transplantation.
Read More
More Info Needed to Establish Utility of MRD, SFLC Levels as Biomarkers in MM
February 12th 2022This new study synthesized data from 5 clinical trials at the University of California, San Francisco, to evaluate the utility of minimal residual disease (MRD) and serum-free light chain (SFLC) levels in predicting progression-free survival among patients with multiple myeloma (MM) receiving chimeric antigen receptor T-cell therapies.
Read More